Targeting PCSK9 for Therapeutic Gains

    Research output: Contribution to journalArticle

    19 Citations (Scopus)

    Abstract

    Even though it is only a little over a decade from the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) as a plasma protein that associates with both hypercholesterolemia and low cholesterol syndromes, a rich literature has developed describing its unique physiology and the impact of antagonism of this molecule on cholesterol metabolism for therapeutic purposes. Indeed, the PCSK9 story is unfolding rapidly, with many answers and more questions. This review summarizes the most recent data from phase II/III clinical trials of PCSK9 inhibition with the three leading antibodies, highlights the clinical significance of the ongoing studies, and suggests future areas of investigation based on recent basic science discoveries on the physiology of PCSK9.

    Original languageEnglish (US)
    JournalCurrent Atherosclerosis Reports
    Volume17
    Issue number4
    DOIs
    StatePublished - 2015

    Fingerprint

    Cholesterol
    Phase III Clinical Trials
    Phase II Clinical Trials
    Therapeutics
    Hypercholesterolemia
    Blood Proteins
    Proprotein Convertase 9
    Antibodies

    Keywords

    • Lipoprotein (a)
    • Low-density lipoprotein
    • Low-density lipoprotein receptor
    • Pleiotropic effects
    • Proprotein convertase subtilisin kexin 9
    • Triglycerdies

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine

    Cite this

    Targeting PCSK9 for Therapeutic Gains. / Shapiro, Michael; Fazio, Sergio; Tavori, Hagai.

    In: Current Atherosclerosis Reports, Vol. 17, No. 4, 2015.

    Research output: Contribution to journalArticle

    @article{c5701b22d3584bafb22866265f25728f,
    title = "Targeting PCSK9 for Therapeutic Gains",
    abstract = "Even though it is only a little over a decade from the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) as a plasma protein that associates with both hypercholesterolemia and low cholesterol syndromes, a rich literature has developed describing its unique physiology and the impact of antagonism of this molecule on cholesterol metabolism for therapeutic purposes. Indeed, the PCSK9 story is unfolding rapidly, with many answers and more questions. This review summarizes the most recent data from phase II/III clinical trials of PCSK9 inhibition with the three leading antibodies, highlights the clinical significance of the ongoing studies, and suggests future areas of investigation based on recent basic science discoveries on the physiology of PCSK9.",
    keywords = "Lipoprotein (a), Low-density lipoprotein, Low-density lipoprotein receptor, Pleiotropic effects, Proprotein convertase subtilisin kexin 9, Triglycerdies",
    author = "Michael Shapiro and Sergio Fazio and Hagai Tavori",
    year = "2015",
    doi = "10.1007/s11883-015-0499-4",
    language = "English (US)",
    volume = "17",
    journal = "Current Atherosclerosis Reports",
    issn = "1523-3804",
    publisher = "Current Medicine Group",
    number = "4",

    }

    TY - JOUR

    T1 - Targeting PCSK9 for Therapeutic Gains

    AU - Shapiro, Michael

    AU - Fazio, Sergio

    AU - Tavori, Hagai

    PY - 2015

    Y1 - 2015

    N2 - Even though it is only a little over a decade from the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) as a plasma protein that associates with both hypercholesterolemia and low cholesterol syndromes, a rich literature has developed describing its unique physiology and the impact of antagonism of this molecule on cholesterol metabolism for therapeutic purposes. Indeed, the PCSK9 story is unfolding rapidly, with many answers and more questions. This review summarizes the most recent data from phase II/III clinical trials of PCSK9 inhibition with the three leading antibodies, highlights the clinical significance of the ongoing studies, and suggests future areas of investigation based on recent basic science discoveries on the physiology of PCSK9.

    AB - Even though it is only a little over a decade from the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) as a plasma protein that associates with both hypercholesterolemia and low cholesterol syndromes, a rich literature has developed describing its unique physiology and the impact of antagonism of this molecule on cholesterol metabolism for therapeutic purposes. Indeed, the PCSK9 story is unfolding rapidly, with many answers and more questions. This review summarizes the most recent data from phase II/III clinical trials of PCSK9 inhibition with the three leading antibodies, highlights the clinical significance of the ongoing studies, and suggests future areas of investigation based on recent basic science discoveries on the physiology of PCSK9.

    KW - Lipoprotein (a)

    KW - Low-density lipoprotein

    KW - Low-density lipoprotein receptor

    KW - Pleiotropic effects

    KW - Proprotein convertase subtilisin kexin 9

    KW - Triglycerdies

    UR - http://www.scopus.com/inward/record.url?scp=84923843937&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84923843937&partnerID=8YFLogxK

    U2 - 10.1007/s11883-015-0499-4

    DO - 10.1007/s11883-015-0499-4

    M3 - Article

    C2 - 25712137

    AN - SCOPUS:84923843937

    VL - 17

    JO - Current Atherosclerosis Reports

    JF - Current Atherosclerosis Reports

    SN - 1523-3804

    IS - 4

    ER -